Chardan Capital reaffirmed their hold rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report released on Thursday morning. They currently have a $50.00 price target on the biopharmaceutical company’s stock.

“We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:.”,” Chardan Capital’s analyst commented.

Several other equities research analysts have also recently issued reports on ESPR. Zacks Investment Research cut Esperion Therapeutics from a hold rating to a sell rating in a research note on Friday, February 8th. Northland Securities reiterated a buy rating and issued a $65.00 price target on shares of Esperion Therapeutics in a research note on Friday, March 1st. JPMorgan Chase & Co. upgraded Esperion Therapeutics from an underweight rating to a neutral rating and boosted their price target for the company from $38.00 to $47.00 in a research note on Wednesday. BidaskClub upgraded Esperion Therapeutics from a sell rating to a hold rating in a research note on Thursday, January 31st. Finally, ValuEngine cut Esperion Therapeutics from a strong-buy rating to a buy rating in a research note on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $73.08.

Shares of ESPR stock traded up $1.61 during trading on Thursday, hitting $50.64. The company had a trading volume of 5,974 shares, compared to its average volume of 575,891. The stock has a market cap of $1.32 billion, a P/E ratio of -6.74 and a beta of 2.17. Esperion Therapeutics has a one year low of $33.06 and a one year high of $79.37.

In other Esperion Therapeutics news, CEO Timothy M. Mayleben bought 5,000 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was purchased at an average cost of $48.73 per share, for a total transaction of $243,650.00. Following the completion of the purchase, the chief executive officer now directly owns 51,163 shares of the company’s stock, valued at $2,493,172.99. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Roger S. Newton sold 25,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $50.06, for a total value of $1,251,500.00. Following the sale, the director now owns 548,726 shares of the company’s stock, valued at $27,469,223.56. The disclosure for this sale can be found here. Insiders have acquired 195,000 shares of company stock valued at $8,406,150 over the last 90 days. Corporate insiders own 14.50% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Esperion Therapeutics by 3.4% during the third quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock worth $3,155,000 after purchasing an additional 2,348 shares during the last quarter. Teachers Advisors LLC increased its holdings in Esperion Therapeutics by 35.1% in the third quarter. Teachers Advisors LLC now owns 62,477 shares of the biopharmaceutical company’s stock valued at $2,772,000 after purchasing an additional 16,237 shares during the period. Rothschild & Co. Asset Management US Inc. increased its holdings in Esperion Therapeutics by 15.4% in the third quarter. Rothschild & Co. Asset Management US Inc. now owns 27,381 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 3,644 shares during the period. Rhumbline Advisers increased its holdings in Esperion Therapeutics by 45.2% in the fourth quarter. Rhumbline Advisers now owns 31,583 shares of the biopharmaceutical company’s stock valued at $1,453,000 after purchasing an additional 9,836 shares during the period. Finally, BlackRock Inc. increased its holdings in Esperion Therapeutics by 4.1% in the third quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock valued at $83,367,000 after purchasing an additional 73,673 shares during the period. Hedge funds and other institutional investors own 99.43% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Return on Equity (ROE)

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.